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Abstract
ATP-Binding Cassette (ABC) transporters are efflux pumps frequently associated with multidrug resistance in many
biological systems, including malaria. Antimalarial drug-resistance involves an ABC transporter, PfMDR1, a homologue of P-
glycoprotein in humans. Twenty years of research have shown that several single nucleotide polymorphisms in pfmdr1
modulate in vivo and/or in vitro drug susceptibility. The underlying physiological mechanism of the effect of these
mutations remains unclear. Here we develop structural models for PfMDR1 in different predicted conformations, enabling
the study of transporter motion. Such analysis of functional polymorphisms allows determination of their potential role in
transport and resistance. The bacterial MsbA ABC pump is a PfMDR1 homologue. MsbA crystals in different conformations
were used to create PfMDR1 models with Modeller software. Sequences were aligned with ClustalW and analysed by Ali2D
revealing a high level of secondary structure conservation. To validate a potential drug binding pocket we performed
antimalarial docking simulations. Using aminoquinoline as probe drugs in PfMDR1 mutated parasites we evaluated the
physiology underlying the mechanisms of resistance mediated by PfMDR1 polymorphisms. We focused on the analysis of
well known functional polymorphisms in PfMDR1 amino acid residues 86, 184, 1034, 1042 and 1246. Our structural analysis
suggested the existence of two different biophysical mechanisms of PfMDR1 drug resistance modulation. Polymorphisms in
residues 86/184/1246 act by internal allosteric modulation and residues 1034 and 1042 interact directly in a drug pocket.
Parasites containing mutated PfMDR1 variants had a significant altered aminoquinoline susceptibility that appears to be
dependent on the aminoquinoline lipophobicity characteristics as well as vacuolar efflux by PfCRT. We previously described
the in vivo selection of PfMDR1 polymorphisms under antimalarial drug pressure. Now, together with recent PfMDR1
functional reports, we contribute to the understanding of the specific structural role of these polymorphisms in parasite
antimalarial drug response.
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Introduction
Efforts to control Plasmodium falciparum malaria are currently
reliant on vector control and chemotherapy. Unfortunately, the
parasite has demonstrated a persistent ability to circumvent
antimalarial drug efficacy through resistance-conferring muta-
tions, as most dramatically illustrated by the collapse of
chloroquine as worldwide mainstay chemotherapy [1]. Lack of
an effective alternative chemotherapy led to a documented rise in
the public health impact of malaria and a significant increase in
the disease’s related mortality [2,3].
A cornerstone event in malaria chemotherapy occurred in
Thailand, during the 1990s: the recovery of the efficacy of
mefloquine (MQ) through its combination with artesunate [4,5].
Following this successful implementation, conceptually similar
artemisinin derivative combination therapies (ACT) were progres-
sively adopted worldwide. Consequently, ACT is presently
recognised as an absolute central factor in P. falciparum malaria
control[6]. Ithasbeenproposedthat P. falciparumresistancetoACT
could evolve [7,8]. Indeed, recent reports have provided the first
indications that resistance to ACTs may be emerging in natural
parasite populations [9,10]. If such resistance spreads widely, our
drug-based efforts to control malaria will be severely held back.
Drug treatments and policies, purposely engineered to avoid the
development of Multi-Drug Resistance (MDR) mechanisms are
urgently required. This challenge demands a fundamental under-
standing of the details of the resistance mechanisms utilised by
P. falciparum.
In higher mammals, the ATP-binding cassette (ABC) super-
family subclass B1, typified by the mammalian P-glycoprotein
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23875(Pgp) [11], have been consistently linked to drug-resistance
phenotypes in a large range of organisms [12]. P. falciparum
contains in its proteome a Pgp-homologue (PfMDR1) [13,14].
Single nucleotide polymorphisms (SNPs) in its coding gene (pfmdr1)
have been shown to be associated with differential in vivo and in
vitro parasite responses to a significant range of central ACT
antimalarial partner drugs, including amodiaquine [15,16],
mefloquine [7,17–19], lumefantrine [8,20] and, importantly,
artemisinin [18,19]. PfMDR1 is hence considered an important
potential candidate for mediating ACT resistance [21,22].
However the biophysics and mechanistic role of these polymor-
phisms remains poorly understood.
In the present study we demonstrate 3D structural models for
PfMDR1 and merge available, but never fully integrated, molecular/
functional data on this transporter and the functional effects of its
main polymorphisms, including in vitro antimalarial susceptibility.
Recent observations of the effects of the clinical use of different
antimalarial upon allele selection are discussed in terms of their
contribution to drug resistance and mechanism of action contrib-
uting to evidence based view of antimalarial implementation.
Results
PfMDR1 structure
PfMDR1 is a member of the ABC protein superfamily. It is a
homologue of Human Pgp-1 composed of two symmetric parts
(defined as domain 1 and 2, from N-terminal to C-terminal). Each
domain has a transmembrane domain (TMD), composed of three
external loops (EL) and two internal helixes (IH) that link six
transmembrane regions (TM) followed by a nucleotide binding
domain (NBD) (Figure S1).
As a reference for our model, we considered the bacterial ABC
lipid flippase (MsbA). This transporter is structurally and
functionally related to eukaryotic MDR-type proteins [23]. The
documented determination of MsbA structures captured in
different conformations allows the basis for structural and motion
extrapolations for other ABC full transporters [24].
Comparison of the PfMDR1 primary and secondary structure
with those of MsbA, revealed the existence of structure/function
conservation between the two proteins, reflected by a ,22%
identity in total homology of PfMDR1 aminoacid residue
sequence. In addition, the alignment showed a righteous match
in the aminoacid type homology and consequently in secondary
structure, pointing towards a structural and functional conserva-
tion (Figure S1).
The main sequence divergence in homology occurs in a part of
the PfMDR1 NBD’s. In NBD1 there is an aminoacid frame
insertion after the Q-loop and in NBD2 the insertion occurs after
the P-loop. Another observed insertion is located in the TM5 and
in its equivalent region of the second domain, designated TM10.
TM5 and TM10 in PfMDR1 are expected to be longer than those
observed to the MsbA structures. The consistence of this
divergence in the homologous halves supports the existence of
symmetry between the two domains of ABC transporters (Figure
S1).
Structural changes in PfMDR1
It has been previously demonstrated that a large range of
motion is required for the MsbA transporter to function [24]. For
PfMDR1, two hinges whose movement allow for different
conformations correspond to EL2 (residue 189–194) and EL3
(residue 311–315) and the equivalent hinge EL5 (residue 929–933)
and EL6 (residue 1055–1059) (Figure 1 A–C).
The TMDs communicate with NBDs through IH contact. A
particular characteristic is the intertwined interface between the
two halves of the transporter, interlocking TM4/TM5/IH2 with
NBD2 and TM10/TM11/IH4 with NBD1. Recently, the
importance of this structural feature for ABC transporter substrate
binding, signalling, and transport was shown. The bonding of the
nucleotide transmits a structural change to the TMs via IH’s,
resulting in an outward-facing conformation activating transport
[25,26].
Pfmdr1 single nucleotide polymorphisms: implications
for PfMDR1 substrate transport capacity
In Africa, two major PfMDR1 variants are found that differ at 3
aminoacid residues: N86Y, F184Y and D1246Y. The haplotype
NFD is associated with decreased parasite sensitivity to arylami-
noalcool quinoline drugs (e.g. mefloquine, lumefantrine). Accord-
ingly, selection of this haplotype has been consistently observed
during artemether-lumefantrine, (CoartemH, Novatis AG, Basel)
treatment [8,20,27], whereas the alternative haplotype YYY, is
linked to decreased sensitivity to 4-aminoquinoline drugs such as
chloroquine and amodiaquine [15,28–31].
EL1 is known to be N-glycosylated in the human multidrug
transporter Pgp-1 [32]. Asparagines at position 84 and 86 in the
EL1 of PfMDR1 were predicted to be glycosylated with a potential
of 0.56 and 0.73 respectively (Figure S2). When we replaced in the
sequence 86N residue for the tyrosine variant (86Y), the potential
glycosylation site was abolished. However, because of the low
N-glycosylation capability in P. falciparum, its physiological impact
remains to be investigated. [33].
For the MsbA transporter, the EL1, which connects TM1 and
TM2, is also proposed to be important in open-apo conformation
stability through contact with EL6 which links TM11 and TM12.
In order to establish a protein nucleotide-bound conformation, the
PfMDR1 EL1 and EL6 split and lose interaction transforming
the transporter in a V-shape (Figure 1A–C). Indeed, in MsbA, the
a.a. residue 56 localized in the EL1 region was shown to interact
covalently through spontaneous disulphide bounding with the
opposing monomer by cysteine cross-linking experiments in the
ATP unbound form [34] demonstrating the proximity between
the EL1 and EL6 loops. A similar structural arrangement has been
reported to occur in human Pgp, highlighting the importance of
TM1 and TM11 terminals at EL’s closeness, in ABC transporters
function [35].
Analyzing the contact residue in the PfMDR1 EL6 we found
that the side-chain of 86Y in EL1 localizes in parallel with residue
1054K (Figure 2A). TM1 and TM11 interactions have been
shown in human Pgp to be fundamental for the correct positioning
of TMs, while modulating the transporter affinity in a drug specific
manner [25,36]. Accordingly, a significant change in drug affinity
caused by the TM1 located N86Y mutation was observed [37]
suggesting an analogous biophysical role when residue 86 is
mutated to a tyrosine.
PfMDR1 a.a. residue 184 is embedded in TM3, facing the
transporter out surface. Analogous to human P-glycoprotein, a
mutation in TM3 was shown to alter transport kinetics,
independent from drug binding capacity [38]. TM3 is located in
the middle of TMD1 surrounded by TM1–TM2 on one side and
TM4–TM6 in the other. TM4 and TM5 are closely associated
with TM3 in the nucleotide bound conformation (Figure 2B).
These major changes, between close and open conformation, are
due to the flexibility of EL3 and EL4, which constitute an
important hinge in the transporter structure from an ‘‘inverted V’’
shape to a ‘‘V’’ shape and enabling membrane transport
interference [24]. In such mobile structures small changes, such
PfMDR1 Structures Models
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may cause disturbance in protein dynamics.
The Y184F SNP appears to alter PfMDR1 kinetics but not drug
specificity [37,39] as showed in the pfmdr1 allelic exchange
experiments investigating antimalarial resistance [18]. When
compared with the other SNPs in PfMDR1, polymorphism at
position 184 exhibit a weaker antimalarial resistance association in
vivo [7,20,40–45].
Polymorphisms located in the NBD of ABC transporters were
reported to alter protein transport kinetics through ATP hydrolysis
capacity alteration [46] or by altering the communication between
the NBD and the transmembrane domains [47]. Residue 1246 is
located in the NBD2 near the Q-loop and is part of the cleft in
NBD2 that interacts with IH2 at the N-terminal (Figure 2C), and
is essential for ABC transporter function [48]. PfMDR1 ATPase
basal activity was shown not to be blocked by the D1246Y
mutation alone. Reduction of PfMDR1 ATPase activity was also
reported to occur only when 1246Y is associated with 1034S or
1042D, but not alone [39].
Our model suggests that the functional impact of the D1246Y
mutation occurs through interference with the NBD/TM
communication, which is required for ABC transporter function.
Furthermore, this effect is substrate specific, since no significant
change was observed in halofantrine or vinblastine transport by
this mutation, suggesting that it is important for substrates which
bind to the TM11 binding pocket (described below), as
demonstrated for QN transport [37].
PfMDR1 drug-binding pocket
Transmembrane regions in ABC transporters are involved in
ligand docking. Among the five naturally occurring functional
PfMDR1 polymorphisms involved in antimalarial resistance, two
are located in TM11, residues 1034 and 1042 (Figure 1D).
Polymorphisms localised in this region of the human homologous
transporter Pgp interfere with drug transport, suggesting the
existence of a drug-binding pocket in this region [49].
In our model, the 1034/1042 and 86 positions co-localize in
three dimension at a close region in the open state conformation of
the protein (V shaped), whereas TM1 and TM11 come closer
(Figure 1A and 1D). Spatial analysis shows that residue 86 in EL1
is in contact with the digestive vacuole (DV) lumen (Figure 1A–C),
while the residues 1034 and 1042 alternate between facing the
cytosol in the open state (V shaped, Figure 1A) and DV lumen in
the closed state (Figure 1C).
Several studies propose residues 1034 and 1042 as part of an
antimalarial binding pocket [19,39]. Using a refined model from
the open state conformation we performed docking analysis in
Figure 1. PfMDR1 structure models. PfMDR1 structures are shown in different conformations: inverted V shape (open-apo) based in bacterial
MsbA 3B5w structure (A), close-apo based in 3B5x (B) and V shape based in 3B60 structure (C). Panel (D) shows localization of residues 86 (EL1), 1034
and 1042 (TM11) in the open state. Dashed green circle represents residue 86 location and red dashed circle 1034 and 1042.
doi:10.1371/journal.pone.0023875.g001
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and 1042 residues as a drug binding site. Mefloquine (MQ),
quinine (QN), and chloroquine (CQ) docked in the proposed
binding site, preferentially interacting with residue 1042. The
energies of docking for the best pose were estimated to be:
26.89 Kcal/mol for CQ (Figure 3A), 27.86 for QN (Figure 3B)
and 25.69 for MQ (Figure 3C).
When residues 1042 and 1034 were mutated, the estimated
docking capacity of binding was altered, strengthening the
hypothesis that these residues are actively involved in the drug
binding site. Introduction of a single mutation 1034C abolished
the docking of MQ and QN but not CQ. CQ binds to the mutated
TM11 (1034C) with an estimated energy of 27.55 Kcal/mol.
The single mutation of N1042D and the double mutation
1034C/1042D abolished the docking of all tested antimalarial.
Cellular physiology of antimalarial transport by PfMDR1
and resistance
Together with PfMDR1, multidrug resistance in P. falciparum
was shown to be highly associated with another gene, the
chloroquine resistance transporter gene (pfcrt). Both transporters
localize in the DV, with opposed directional flux characteristics.
PfMDR1 is proposed to be a DV importer [50] whilst PfCRT was
shown to be an antimalarial DV exporter [51]. To study the
physiology of PfMDR1/PfCRT interference towards antimalarial
resistance, we evaluate the contribution for antimalarial resistance
of isogenic PfMDR1 mutant’s clones with a CQ resistant (7G8) or
sensitive (D10) genetic background (Table S1).
The target for antimalarial aminoquinoline is well known to be
the parasite’s DV. For this reason, chloroquine (CQ), amodiaquine
(AQ) and desethylamodiaquine (DEAQ) were used as probe drugs.
In order to study in exclusive the effect of PfMDR1 mutations,
verapamil was used to block the PfCRT 76T variant.
To test the contribution of PfMDR1 for aminoquinoline we
compared the index of resistance between parasites harbouring a
wild type (SND) or resistant (CDY) haplotype at residues 1034,
1042 and 1246. These experiments were conducted in two
different pfcrt genetic backgrounds carrying a 76T (7G8) or 76K
allele (D10).
Our results show that PfMDR1 contributed to resistance for all
tested antimalarial. The differential effect of PfMDR1 for different
aminoquinoline susceptibility was as follow: chloroquine,amo-
diaquine,desethylamodiaquine (Fig. 4). This association is related
with the lipophobicity characteristics of the tested drugs and the
PfCRT background. The corresponding Log D (pH 7.2) values for
these drug are CQ:0.045,(DEAQ:1.183,AQ:2.60) (taken from
[52]). In general, the involvement of PfMDR1 was stronger for
AQ and DEAQ than the effect observed for CQ.
In the PfCRT 76K background (D10), the contribution of
PfMDR1 was observed even for CQ while in 7G8 clone (76T) is
only detected for DEAQ. Although, when PfCRT is blocked with
verapamil in 7G8 clone, a significant increase is observed also for
AQ to levels comparable with D10 index for AQ (Fig. 4).
These observations support the hypothesis that PfMDR1 is a
vacuolar importer. In the presence of the mutant PfMDR1
(blocking antimalarial DV import), sensitivity to aminoquinoline is
driven by its capacity to passively enter the DV membrane,
demonstrated here through the correlation between the PfMDR1
resistance index and aminoquinoline lipophobicity characteristics.
Interestingly, taken together with the inverse association of
aminoquinoline lipophobicity pattern for PfCRT-based resistance,
an explanation may present itself for the in vivo co-selection of
opposed functional haplotypes (highly effective PfCRT efflux
and deficient PfMDR1 influx transporters) to reduce the dynamics
of aminoquinoline accumulation in the DV, especially for
hydrophobic compounds.
Figure 2. Structural localization of PfMDR1 polymorphisms. A)
Interaction of EL1-EL6 aromatic side-chain of residue 86Y approximation
to the cationic side-chain 1054K in the resting state. Interaction is
shown in the Van der Waals surface (dark orange) between the O (red
atom) of the 86Y side-chain with N (blue atom) in 1054K side-chain. B)
Location of residue 184 in TM3 shown in two different conformation
structures - open (red) and close (blue). C) Location of residue 1246 in
NBD2 - Residue 1246 surface is shown in red localized in the cleft
interacting with IH2 (yellow aminoacids surface) in the opposed
domain.
doi:10.1371/journal.pone.0023875.g002
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In the present work we propose a model for PfMDR1 structure
and motion during transport. The existence of extensive literature
describing the functional and molecular epidemiologic impact of
polymorphisms in this transporter together with knowledge of the
structure of ABC transporters, made it possible to predict the
functional role of mutant residues in PfMDR1.
Our structural analyses, in the light of previous allelic exchange
and transport kinetics studies [18,19,37,39], demonstrate the
existence of an internal allosteric modulation of protein transport-
ing capacity by the three key polymorphisms herein studied.
Accordingly, PfMDR1 variant 86Y/184Y/1246Y relates to a
PfMDR1 low-performance quinoline antimalarial transporter.
The inverse variant (86N/184F/1246D) relates to a higher-
performance PfMDR1 transporter, being coherently associated
with gene copy number amplification and its effects in terms of
enhanced resistance to MQ and QN [7,53].
The two most common PfMDR1 selected variants observed in
African parasite populations harbour 86N/184F/1246D or 86Y/
184Y/1246Y [8,15,20,28]. Hence, the suggested altered allosteric
control of transporter activity proposed by the model seems to be
the main molecular phenotype associated with the influence of
PfMDR1 in African parasites.
Figure 3. Docking of antimalarial in TM11. Docking of CQ (A), QN (B) and MQ (C) at residues 1042 and 1034 (serine and aspartic acid
respectively) in TM11 is shown. The energies of docking for best pose were estimated to be 26.89 Kcal/mol for CQ, 27.86 Kcal/mol for QN and
25.69 Kcal/mol for MQ.
doi:10.1371/journal.pone.0023875.g003
Figure 4. Contribution of PfMDR1 for antimalarial resistance. PfMDR1 Resistance Index (RI) was calculated, for each given antimalarial, as
follow: for D10 - RI=D10
CDY EC50/D10
SND EC50 and equally for 7G8 - RI=7G8
CDY EC50/7G8
SND EC50. Verapamil was used to block PfCRT.
doi:10.1371/journal.pone.0023875.g004
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to phenotype modulation by altering a drug pocket in PfMDR1.
The contact of residue 86 with the end of TM11 may explain an
observed change in drug specificity through the alteration of
PfMDR1 drug pocket conformation [37]. Polymorphisms in
TM11 are geographically fixed in Asia and South America. This
observation suggests that different genetic background/environ-
ment defines the fixation of a particular mechanism for PfMDR1
functional modulation.
From a mechanistic perspective, the haplotype encoding 86N,
1034S, 1042N and 1246D residues is related to a functional
PfMDR1 importer into the DV [50]. Again, field observations
show this haplotype to be related to mefloquine and lumefantrine
resistance [7,8,20,53]. This importer variant is oppositely related
(promotes sensitivity) to CQ and amodiaquine (AQ) which acts
within the DV [15,28–31].
From a dynamic perspective, PfCRT antimalarial vacuolar
efflux may affect the contribution of PfMDR1 to resistance.
Supporting the hypothesis of a vacuolar antimalarial accumulation
dynamic through PfCRT/PfMDR1 interaction, is the natural
selection of functionally inversed polymorphisms of PfCRT and
PfMDR1. PfCRT 76T promotes vacuolar efflux [54,55] and is
associated with PfMDR1 86Y (abrogates quinolines transport)
[37]. Both forms are selectively associated with, as for example,
CQ and AQ malaria chemotherapy [15,28–31]. Oppositely,
PfCRT 76K with PfMDR1 86N are associated with selection by
aminoalcohol antimalarial drugs, such lumefantrine [8,56].
Based on different genetic backgrounds, PfCRT/PfMDR1
dynamics can be either pro- or con- tolerance as has been
previously reported to occur in a compensatory manner depending
on the mechanism of action of the antimalarial [57].
We previously reported the importance of natural selection of
different variants of PfMDR1 with different antimalarial chemo-
therapies [8,15,20,28]. Now we describe how residues in PfMDR1
may be involved in drug resistance using a structural model.
In conclusion, we describe a model for structural changes
associated with transport motion and we suggest the presence of a
drug binding pocket in PfMDR1. Our results support recent
findings suggesting this transporter as being a vacuolar antima-
larial importer and propose a structural basis for the importance of
residues 86, 184, 1034, 1042 and 1246 for drug specificity and
how mutations at these residues may interfere with the
composition of a drug pocket in TM11. The proposed models
are expected to contribute to the prediction of the effects of other
less studied PfMDR1 SNPs, while being a potential tool for the
design of antimalarial drugs targeting this essential P. falciparum
transporter.
Materials and Methods
Parasites and drug susceptibility assays
Four P. falciparum clones in which the pfmdr1 1034, 1042 and/or
1246 loci have been modified through allelic exchange [18] were
selected for this study. They were obtained from the Malaria
Research and Reference Reagent Resource Center (MR4). Two
clones were derived from the CQ sensitive D10 clone from Papua
New Guinea i.e MRA-563: D10 pfmdr1 SND (autologous
transfectant) (D10
SND) and MRA-565: D10 pfmdr1 CDY
(D10
CDY). Two clones were derived from the CQ resistant clone
7G8 from Brazil i.e MRA-566: 7G8 pfmdr1 SND (7G8
SND) and
MRA-567: 7G8 pfmdr1 CDY (autologous transfectant). The clones
were defrosted, adapted to continuous culture in supplemented
RPMI-1640 and 5% haematocrite and then synchronized with
sorbitol, according to established protocols.
The influence of the pfmdr1 1034C, 1042D and/or 1246Y SNPs
on parasite response to CQ, AQ and DEAQ was determined with
an HRP2-ELISA based assay in vitro as previously described [58].
In vitro cultured parasites were diluted to an initial parasitemia of
0.05% and aliquoted into microculture 96-well plates pre-dosed
with ascending concentrations of 0–404 nM CQ, 0–67 nM AQ or
0–156 nM DEAQ. We also added VP 0.8 mM to a parallel setup.
After incubation at 37uC for 72 h, the samples were freeze-
thawed, transferred and processed in pre-coated ELISA plates
(Cellabs, Australia) for spectrophotometric analysis (Multiskan EX,
Thermo LabsystemsH, Helsingfors, Finland) of HRP2 produced
during parasite growth. The IC50 and values were determined
using HN-NonLin V1.05 Beta  H. Noedl 2001 (http://malaria.
farch.net).
Modelling
Protein sequences and structures from bacterial MsbA 3B5w
(open-apo with inverted V shape), 3B5x (closed-apo) and 3B60
(open-apo with V shape) upon nucleotide-bind were downloaded
from PDB database (www.pdb.org). PfMDR1 sequence is
deposited in NCBI Protein database with accession number
XP_001351787.
Sequences were aligned with blosum62 matrix in MultiAlin
server [59] with manual refinement. Since MsbA is formed by a
homodimer, PfMDR1 sequence was analyzed dividing sequence
protein in the two symmetric halves and terminals trimmed to the
homologous TMD and NBD. Residues 37–642, corresponding to
TMD1 and NBD1 and residues 763–1400 corresponding to
TMD2 and NBD2, were used in the alignment.
Alignment was then analyzed with Ali2D software (http://
toolkit.tuebingen.mpg.de/ali2d), developed by the Department of
Protein Evolution, Max-Planck-Institute for Developmental Biol-
ogy (Germany) for sequence identity and secondary structure
similarities. Secondary structure was determined with Psipred
algorithm [60] and aminoacids group coloured with Mview [61].
Models were generated using Modeller software [62]. For
structures modelling and analysis, divergent residues 479–486 and
496–531 in NBD1, IH4 987–998 and residues 1181–1227 were
absent in the alignment. MaxSprout software at European
Bioinformatics Institute server was used to generate protein
backbone and side chain co-ordinates from the C-(alpha)
trace [63]. The halves of the transporter were assembled by
superimposition in the MsbA structures using the Mustang
algorithm and adjusted manually [64]. Yasara [65] and WinCoot
[66] software were used for visualization and refinement.
N-Glycosylation sites prediction
Prediction of N-Glycosylation sites at the EL1 was performed
using NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/
NetNGlyc/). The protein sequence including the predicted EL1
plus four boundary aminoacids comprising residues 79–91 was
evaluated. A threshold of 0.5 was applied.
Drug pocket modeling and docking
The model based in the 3B5w structure was further refined in
WinCoot for docking studies. Docking was performed with
Arguslab software [67]. Residues 1034 and 1042 in TM11 were
defined as drug binding pockets and docking boxes defined as
minimum volume for binding of 12.5613612.5 A ˚ for CQ and
QN and 13613613 A ˚ for MQ were used. Best pose for the lowest
energy of binding was considered. The CQ, QN and MQ
structures were design and refined at PRODRG2 server [68].
PfMDR1 Structures Models
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Figure S1 Protein sequences alignment of PfMDR1 and
different MsbA structures. The alignment describes the
primary percentage of overall matching between PfMDR1 protein
as well as secondary and tertiary structures features. Aminoacids
letters are coloured by group identity default palette defined by
Mview software. Background colour shows secondary structure,
grey - coiled; brown- helix and yellow- beta-sheet. On top of the
alignment is annotated the ABC conserved motifs as well as main
structural characteristics: TM-transmembranes; EL- external loop;
IH- internal helix. Stars identify functional residues in PfMDR1
transport: N86Y, Y184F, S1034C, N1042D and D1246Y.
(PDF)
Figure S2 N-glycosylation sites prediction. External loop
1 sequence (residues 79–91) was screened for putative
N-glycosylation sites. Two asparagines localize in this loop at
positions 84 and 86. Predictive potential sites obtained with
NetNglyc 1.0 software.
(PDF)
Table S1 PfCRT and PfMDR1 coding genotypes for
clones D10
SND, D10
CDY, 7G8
SND and 7G8
CDY.
(PDF)
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